SYSTEMATIC REVIEW article
Front. Psychiatry
Sec. Schizophrenia
This article is part of the Research TopicBiomarker Discovery and Validation in Neurological DiseasesView all 7 articles
The Relationship between Total Tau Protein, Phosphorylated Tau Protein, Schizophrenia and Bipolar Disorder: A Systematic Review and Meta-Analysis
Provisionally accepted
- 1Capital Medical University, Beijing, China
- 2University of New South Wales, Sydney, Australia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Neurodevelopmental disorders, notably schizophrenia, continue to pose major challenges in mental health and clinical practice. Numerous studies have posited potential associations between tau proteins and schizophrenia or bipolar disorder (BD), yet these associations have not been systematically described or quantitatively examined. This study aims to compare total tau and phosphorylated tau levels in plasma、serum (collectively referred to as peripheral blood), and cerebrospinal fluid (CSF) between individuals with schizophrenia and healthy controls, and to further examine total tau levels in BD. Methods: Employing a meticulous search strategy across PubMed, Embase, Medline and Web of Science, this study adheres to PRISMA guidelines. Eligible studies were non-randomized controlled trials investigating associations between tau proteins, schizophrenia or BD. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated. This study protocol has been registered on PROSPERO (CRD420251123530). Results: 10 studies were included in the meta-analysis. Total tau levels were significantly lower in patients with schizophrenia compared to controls in CSF (SMD = -0.33, 95% CI: [-0.59, -0.08] ) and peripheral blood samples (SMD = -0.88, 95% CI: [-1.61, -0.15] ). Combining both samples, the overall SMD was -0.48 (95% CI: [- 0.66, -0.31]), indicating a significant reduction in total tau levels. The pooled analysis for phosphorylated tau group yielded an SMD of -1.07 (95% CI: [-1.55, -0.59]), with consistent findings in CSF samples (SMD = -0.76, 95% CI:[ -1.17, -0.35]). In contrast, total tau levels did not differ significantly between patients with BD and healthy controls (SMD = -0.07, 95% CI: [-0.26, 0.12]), Data were insufficient to support a meta-analysis of the relationship between phosphorylated tau and BD. Conclusion: T-tau and p-tau protein levels are lower in schizophrenia patients compared with healthy controls, whereas no significant difference was observed in BD patients. These findings may have potential for clinical diagnostics.
Keywords: bipolar disorder, Meta - analysis, Schizophrenia, Tau phosphorylation, total tau (t-tau)
Received: 09 Dec 2025; Accepted: 11 Feb 2026.
Copyright: © 2026 Hou, Chen, Chang and Huo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chunyue Huo
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.